Cytokinetics Inc CYTK

Healthcare Biotechnology

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporate...

NDAQ:CYTK - Post by User

Cytokinetics Inc

Bullboard Posts

(0)
•••

Post by lovetheoilpatchon Apr 19, 2014 10:44pm

341 Views

Post# 22469880

ill ask the board a question....

Since I know people are reading lol.....will cytk continue the uptrend. .....is this a sign that positive results are imminent. ...does cytk have a legit shot at 25 a share.....and in the short term. ...what do some of you expect

Bullboard Posts

Scams surge as the fastest-growing consumer threat